Kraml M - Search Results

1

Pharmacokinetics of cetamolol in hypertensive patients with normal and compromised renal function.

Skoutakis VA, Acchiardo SA, Carter CA, Ingebretsen CG, Klausner MA, Lee DK, Kraml M. Skoutakis VA, et al. Among authors: kraml m. J Clin Pharmacol. 1988 May;28(5):467-76. doi: 10.1002/j.1552-4604.1988.tb05762.x. J Clin Pharmacol. 1988. PMID: 2899095

2

Comparative pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol.

Garg DC, Jallad NS, Mishriki A, Chalavarya G, Kraml M, Fencik M, Weidler DJ. Garg DC, et al. Among authors: kraml m. J Clin Pharmacol. 1987 May-Jun;27(5):390-6. doi: 10.1002/j.1552-4604.1987.tb03036.x. J Clin Pharmacol. 1987. PMID: 3693583 Clinical Trial.

3

Pharmacokinetics and disposition of the lipid-lowering drug acifran in normal subjects and in patients with renal failure.

Cayen MN, Ferdinandi ES, Hicks DR, Gonzalez R, Cosyns L, Dubuc J, Kraml M, Edwards KD. Cayen MN, et al. Among authors: kraml m. Clin Pharmacol Ther. 1990 Jan;47(1):50-6. doi: 10.1038/clpt.1990.7. Clin Pharmacol Ther. 1990. PMID: 2295219

4

The effect of renal disease on tolrestat pharmacokinetics.

Troy SM, Hicks DR, Kraml M, Conrad K, Chiang ST. Troy SM, et al. Among authors: kraml m. Clin Pharmacol Ther. 1992 Mar;51(3):271-7. doi: 10.1038/clpt.1992.22. Clin Pharmacol Ther. 1992. PMID: 1544287

5

Pharmacokinetics of the aldose reductase inhibitor tolrestat: studies in healthy young and elderly male and female subjects and in subjects with diabetes.

Fruncillo R, Troy S, Parker V, Mayersohn M, Hicks D, Kraml M, Battle M, Chiang S. Fruncillo R, et al. Among authors: kraml m. Clin Pharmacol Ther. 1996 Jun;59(6):603-12. doi: 10.1016/S0009-9236(96)90000-4. Clin Pharmacol Ther. 1996. PMID: 8681485 Clinical Trial.

6

Etodolac kinetics in the elderly.

Scatina J, Hicks D, Kraml M, Weidler D, Garg D, Sanda M. Scatina J, et al. Among authors: kraml m. Clin Pharmacol Ther. 1986 May;39(5):550-3. doi: 10.1038/clpt.1986.94. Clin Pharmacol Ther. 1986. PMID: 2938866

7

The pharmacokinetics of etodolac in serum and synovial fluid of patients with arthritis.

Kraml M, Hicks DR, McKean M, Panagides J, Furst D. Kraml M, et al. Clin Pharmacol Ther. 1988 May;43(5):571-6. doi: 10.1038/clpt.1988.75. Clin Pharmacol Ther. 1988. PMID: 2966693

8

Comparative bioavailability of propranolol: twice-daily versus four times-daily administration.

Dvornik D, Kraml M, Dubuc J, Patterson-Kreuscher S, Milosovich G, Mullane JF. Dvornik D, et al. Among authors: kraml m. J Clin Pharmacol. 1981 Nov-Dec;21(11):472-6. doi: 10.1002/j.1552-4604.1981.tb05652.x. J Clin Pharmacol. 1981. PMID: 7334139

9

Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin.

Ermer JC, Hicks DR, Wheeler SC, Kraml M, Jusko WJ. Ermer JC, et al. Among authors: kraml m. Clin Pharmacol Ther. 1994 Mar;55(3):305-16. doi: 10.1038/clpt.1994.31. Clin Pharmacol Ther. 1994. PMID: 8143396 Clinical Trial.

10

Tolrestat kinetics.

Hicks DR, Kraml M, Cayen MN, Dubuc J, Ryder S, Dvornik D. Hicks DR, et al. Among authors: kraml m. Clin Pharmacol Ther. 1984 Oct;36(4):493-9. doi: 10.1038/clpt.1984.209. Clin Pharmacol Ther. 1984. PMID: 6478735

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

67 results

Search Page